Page 1 of 31

AYMAN OMAR, MD, PhD, MSc (Oxon), LMCC, DABPN

Neurologist / Neurological Oncologist / Neuroscientist / Specialist in

Endovascular Neurosurgery Email:braindr11@yahoo.com

https://www.linkedin.com/in/aymanomarmd

www.BrainTumorExperts.org Cell: 224-420-2453

CURRENT TITLE:

May 2013 – Present President and Founder Neurology and NeuroOncology Consultant, LLC Providing specialized consulting services in

Neurology and Neurological Oncology

May 2013 - Present Locum Attending Neurologist and NeuroOncologist CompHealth, OnyxMD and Vista Staffing Solutions

Practicing in 4 states: IL, IN, MO and KS

EDUCATION

Premedical

01/1985 - 01/1986 General Certificate of Education (GCE 6As and 2Bs) University of London, School Examinations Board

London, UK (Through the British Council in Stockholm and Cairo)

10/1982 - 7/1985 International Baccalaureate (IB) (completed 3 year program of study) Norra Real Gymnasium - High School

Stockholm, SWEDEN

Page 2 of 31

Medical School

10/1986 - 12/1992 Doctor of Medicine (MBChB) (Awarded Medical Degree with

Honors

University of Cairo Cairo, EGYPT

Graduate Studies

10/2014 - 10/2015 Master of Science (MSc) in Endovascular Neurosurgery University of Oxford Nuffield Department of Surgery

St. Peter’s College Oxford, UK

09/1999 - 10/2002 Doctorate in Philosophy (PhD) (GPA: 3.83/4.0)

Neuroscience / Cellular and Molecular Medicine University of Ottawa

Faculty of Graduate and Postdoctoral Studies (FGPS) Ottawa, CANADA

01/1998 - 09/1999 Master of Science (MSc), Anatomy and Neurobiology

(Recommended to Ph.D. Program due to exceptional progress without completion of a Masters thesis) University of Ottawa

Dept. of Cellular and Molecular Medicine Ottawa, CANADA

06/1995 - 10/1995 Program of Study, Lab Technology and Electron Microscopy

Seneca College of Applied Arts and Technology Toronto, ON, CANADA

Page 3 of 31

CLINICAL TRAINING

Internships

6/1/1993 - 10/31/1993 House Officer (Rotational Intern) 12/1/1995 - 6/30/1996 Cairo University Teaching Hospitals Received intensive 12 months training in the following areas:

Neurosurgery and Neuro-traumatology: 8 wks; General and Vascular Surgery: 8 wks; Orthopedics: 4 wks; Emergency Surgery:

4 wks; OB/GYN: 8 wks; General Pediatrics and neonatal intensive care: 8 wks; General Internal Medicine: 8 wks.

07/2002 – 6/2003 Intern in Internal Medicine

University of Missouri – Columbia Harry S. Truman Memorial Veterans Administration Hospital Columbia, MO, USA

Residency and Chief Residency 07/2005 - 7/2006 Chief Resident in Neurology

University of Missouri - Columbia Harry S. Truman Memorial Veterans Administration Hospital

Columbia, MO, USA

07/2003 - 7/2005 Resident in Neurology University of Missouri - Columbia, MO, USA

Harry S. Truman Memorial Veterans Administration Hospital, Columbia, MO, USA

My responsibilities included admitting, evaluating and managing patients on Neurology inpatient, consult, acute stroke call, EMG,

EEG, sleep studies etc. Additional privileges at the Rusk Rehab as well as Columbia Regional Hospital.

Clinical and Research Fellowships

10/2014 - 10/2015 Fellow (Specialist Registrar) in Endovascular Neurosurgery

University of Oxford Hospitals NHS Trust John Radcliffe Hospital

Oxford, UK

Page 4 of 31

7/2014 - 9/2014 Mini-fellowship / Course (3 months) Cleveland Clinic Foundation

Department of Neurology, Epilepsy Center Cleveland, OH

Training in Epilepsy, epilepsy surgery, Electroencephalography both adult and pediatric, invasive testing including depth electrodes

and subdural grid interpretation, Evoked Potential interpretation, Polysomnography, Intraoperative monitoring and clinical neurophysiological techniques

7/2006 – 7/2008 Clinical Fellow and Research Fellow in Neurological Oncology University of Toronto Princess Margaret Hospital, Pencer Brain Tumor Center

Department of Medicine, Division of Hematology and Oncology Toronto, ON, CANADA

07/2000 – 7/2002 Canadian Institutes of Health Research (CIHR/MRC) Fellow

Canadian Institutes of Health Research Ottawa Health Research Institute, Ottawa Hospital

University of Ottawa Division of Neurosciences

WORK EXPERIENCE:

7/29/2013 - 7/31/2015 Adjunct Assistant Professor of Neurology Southern Illinois University School of Medicine State of Illinois

Springfield, IL

6/3/2013 - Present Internal Medicine Locum Physician Kindred Hospital

Peoria, IL Manage long term acute care (LTAC) patients including critical

care issues and General Internal Medicine

Page 5 of 31

6/7/2010 – 7/29/2013 Program Director and Division Chief of Neurological Oncology Assistant Professor of Clinical Neurology

Southern Illinois University School of Medicine State of Illinois

Springfield, IL Built the first NeuroOncology Program in Central and Southern Illinois

6/7/2010 – 7/29/2013 Staff Attending Physician, Dept. of Neurology St. John’s Hospital Sisters Network Springfield, IL

6/7/2010 – 7/29/2013 Staff Attending Physician, Dept. of Neurology Memorial Medical Center Springfield, IL

6/7/2010 – 7/29/2013 Director, Division of NeuroOncology Simmons Cancer Institute (SIU School of Medicine) Springfield, IL

7/1/2009 - 3/31/2010 Clinical Assistant Professor of Neurology

University of Chicago, Pritzker School of Medicine Biological Sciences Division Chicago, IL

8/1/2008 - 3/31/2010 Attending Neurologist and NeuroOncologist NorthShore University HealthSystem

Evanston, IL

01/1997 - 06/1997 Internal Medicine Physician (Private Practice) Nile Badrawi Hospital

Cairo, Egypt My responsibilities included management of inpatients as well as

outpatients (including neurology, cardiology, pulmonology, oncology, gastroenterology, and a wide variety of general internal

medicine cases). In addition, I was responsible for the monitoring of 30 regular hemodialysis patients as well as post-op care of renal transplant recipients. The department received 30-50 patients daily

including those admitted through HMO’s covering the Middle East region, (Middle East Medicare Plan).

Page 6 of 31

07/1996 - 10/1996 Internal Medicine Physician (Private Practice) Al-Salam Hospital

Cairo, Egypt

My responsibilities included management of patients admitted to the ICU and CCU in addition to the Dialysis Unit, where I monitored patients and performed preoperative workup and

postoperative care of renal transplant recipients.

LICENSURE:

1. United Kingdom, General Medical Council, Full Registration with a license to

practice, granted January 31, 2015, GMC # 7480950

2. State of Missouri, Permanent Physician and Surgeon License, issued October 2013

3. State of Kansas, Permanent Physician and Surgeon License, issued March 2014

4. State of Illinois, Physician and Surgeon Permanent License, 2008

4. State of Indiana, Permanent Physician License, License #01062696A, 2006

5. Canada, Province of Ontario, Member, College of Physicians and Surgeons of Ontario,

License # 85030, 2006 (Expired)

6. Egypt National Medical License, General Medical License (Full Registration), Ministry

of Health, Egypt, 1996 (Permanent)

7. State of Missouri Temporary License, Physician and Surgeon Temporary License for

training, USA, 2002 - 2006 (Expired)

Page 7 of 31

CERTIFICATIONS:

1. The international English language testing system (IELTS) (University of Cambridge

English Language Exam) Scored Band 8 out of 9: First attempt November 2014 2. Radiation Protection and Radiation Physics course (4 months) - Completed January 2015.

Course accredited by the UK Royal Society of Radiologists

3. Good Clinical Practice Training: John Radcliffe Hospital, Oxford, UK, May 2015 4. Oxford Aneurysm Treatment School course: Passed 2015

5. European Course on Minimally Invasive Neurological Therapy (ECMINT1): Passed

6. European Course on Minimally Invasive Neurological Therapy (ECMINT1.2): Passed June

24-27, 2015

7. Certified, National Institutes of Health Stroke Scale, National Stroke Association, 10/13-

10/15 8. Board Certified, American Board of Psychiatry and Neurology, Jan. 14, 2011

9. Licentiate of the Medical Council of Canada (LMCC), 2006

10. Medical Council of Canada Qualifying Examination, Part II (MCCQE II), 2005 11. Medical Council of Canada Qualifying Examination, Part I (MCCQE I), May, 2000

12. Medical Council of Canada Evaluating Examination (MCCEE), September, 1999

13. Certified by the Educational Commission for Foreign Medical Graduates (ECFMG),USA (1998)

14. United States Medical Licensing Examination (USMLE), Step 3, 2008

15. United States Medical Licensing Examination (USMLE), Step 2CS, 2008 16. United States Medical Licensing Examination (USMLE), Step 2, March, 1996

17. United States Medical Licensing Examination (USMLE), Step 1, June, 1995

18. Cert. Basic Cardiac Life Support (BCLS) Provider, St. John Ambulance, Ottawa, 1999, Re-

certified in 2002 and 2004 and February 6, 2014 and UK BLS and PLS Certified in June

2015.

19. Cert. Advanced Cardiac Life Support (ACLS) Provider, American Heart Association, 1999, Re-certified in 2002, 2004 and April 13, 2014

Page 8 of 31

20. Cert. Advanced Trauma Life Support (ATLS) Provider, American College of Surgeons,

April, 2000

21. Test of English as a Foreign Language (TOEFL); score: 290 (CBT; 99th percentile) 22. Test of Spoken English (TSE), February 2000; score: 60 (99th percentile)

23. Completed course on Minimizing Healthcare Errors with Crew Training International

designed for healthcare professionals using fighter jet pilot standards. 24. Completed New Formulations for Anti-Epileptic Drugs, AB Comm. Inc., May, 2004

25. Certified in Institutional Review Board (IRB) policies and procedures for conducting clinical

research (12/31/05) 26. Certified in Health Sciences Health Insurance Portability and Accountability Act (HIPAA)

guidelines (12/31/2005)

27. National Institutes of Health (NIH), National Cancer Institute (NCI) Investigator number assigned since 2008

28. Successfully completed the Collaborative Institutional Training Initiative (CITI), 2011. This is an international course designed to educate researchers on international, local and FDA

regulations designed for the appropriate and ethical conduct of research involving human subjects. Course includes 28 modules and additional modules for IRB members (completed all modules).

29. Ethics Training for University Employees (Online Course), 2011 and 2012

30. Certified in NovoTTF-100A alternating electric current delivery system used to treat

recurrent glioblastomas through placement of transducer arrays directly on a patients skull.

Established the first and only ‘clinical center of excellence’ for NovoTTF-100A system

in central and southern Illinois and one of only ~40 centers nationwide

(http://www.novottftherapy.com/patients-centers.php)

HONORS & DISTINCTIONS:

1. Named “Medical Innovator” for 2013 by the Sangamon County Medical Society and

the Springfield Mayor for “Innovations in the treatment of brain and spinal cord tumors”. Honored in an award ceremony by the Mayor of Springfield, Mike Houston on March 7, 2013.

Page 9 of 31

2. Awarded Chief Residency in Neurology - University of Missouri - Columbia (2005-2006)

3. Travel Fellowship from the American Neurological Association (nation-wide

competition) to attend ANA meeting in Toronto, ON, Canada; Funding: $500.00, October 2-6, 2004

4. Scored in the top 1% in North America in the Neurology Residency In-Service Training

Exam (RITE), American Academy of Neurology, 2003 and 2004

5. Selected as one of the top 150 internationally-trained physicians in the Ontario IMG

Program Entrance Exam, University of Toronto, December, 2001

6. Travel Award from the University of Ottawa, Faculty of Graduate and Post-Doctoral Studies to present poster at the Society for Neuroscience, 31st annual meeting, San Diego, Ca, November, 2001

7. Prize for Outstanding Achievements, Ottawa Hospital Foundation, Ottawa, Canada,

November, 2000

8. Post-Doctoral Fellowship Award, Canadian Institutes of Health Research (CIHR) under

the Canadian Neurotrauma Research Program (CNRP); Ranked: 6th nationwide, June, 2000; Title of Project: Rapid Tissue Remodeling in Dentate Gyrus of Adult Rat

Hippocampus Following Excitotoxic Injury. Funding: $120,000; Fellowship Director: Bin Hu, MD, PhD

9. Excellence Scholarship in Science and Engineering (PhD), University of Ottawa, Faculty of Graduate and Post-Doctoral Studies; Funding: $15,000, June, 2000

10. Graduate Admission Scholarship in Science and Engineering (PhD), University of

Ottawa, Faculty of Graduate and Post-Doctoral Studies; Funding: $5,000, January, 2000

11. Travel Award from the University of Ottawa, Faculty of Graduate and Post-Doctoral

Studies to present poster at the Society for Neuroscience, 29th annual meeting, Miami Beach, FL, October, 1999

12. Awarded Medical Degree with Honors, University of Cairo, December, 1992

13. Scholarship of Academic Excellence, University of Cairo, 1987-1992, awarded annually

14. Travel Award from the IFMSA (World Health Organization) to attend Emergency Surgery

Clerkship at University Clinical Hospital, Zaragoza, Spain, 1991

15. Admission Scholarship, University of Cairo, Faculty of Medicine, 1986

Page 10 of 31

16. Admission Scholarship, American University in Cairo, Mechanical Engineering, 1985, declined

MEDIA COVERAGE

Peoria Journal Star. Electric field treatment takes aim at brain cancer. December 26, 2012 http://www.pjstar.com/article/20121226/News/312269854

State Journal Register, Springfield, IL February 13, 2013. Medical innovators to be honored March 7. News about being selected for the medical innovator award.

State Journal Register, Springfield, IL December 3, 2012.. Electric fields extend life for

some brain cancer patients. Read more: http://www.sj-

r.com/article/20121203/News/312039867#ixzz389aJ5V8E

Aspects Magazine. (Featured on Cover). January 19, 2013. Target: Tumors

http://www.siumed.edu/pubs/aspects/36-1/feature1.html

Simmons Cancer Institute Newsletter, Winter 2012. A new standard of care for Glioblastoms. http://www.siumed.edu/cancer/pdf/newsletter/Winter2013.pdf

Brainscan, Fall 2006. Profile Article for the Pencer Brain Trust. http://www.pencerbraintrust.com/downloads/newsletters/brainscan_fall06.pdf

Sangamon County Medical Society July/August 2013 Newsletter. Eleven Medical Professionals

Honored at Medical Innovators Program, Ayman Omar, M.D., Ph.D., SIU School of Medicine, for his novel approaches to treat brain and spinal cord tumors.

http://www.scmsdocs.org Sangamon County Medical Society. Medical Innovators 2013.

http://www.scmsdocs.org/pdf/medinnovators2013.pdf

Page 11 of 31

RESEARCH AND ACADEMIC FUNDING:

• Principal Investigator (authored study design and protocol): Bevacizumab in

combination with alternating electric fields for the treatment of recurrent glioblastoma

NovoCure, Inc., Portsmouth, NH Developer of FDA-approved NovoTTF Technology

Funding: $5000

• Postdoctoral Fellowship Award (National Award)

Canadian Institutes of Health Research (CIHR) Funding: $120,000, June 2000

• Excellence Scholarship in Science and Engineering

University of Ottawa Funding: $15,000, June 2000

• Travel Award (National award competition – 4 selected)

American Neurological Association Attended ANA meeting in Toronto, ON, CANADA

Funding: $500, 2004

• Travel Award to present research findings at Society for Neuroscience, San Diego

Meeting

University of Ottawa Funding: $500, 2001

• Travel Award to present research findings at Society for Neuroscience, Los Angeles

Meeting

University of Ottawa

Funding: $500, 1999

• Graduate Admission Scholarship in Science and Engineering (PhD)

University of Ottawa

Funding: $5,000, January, 2000

• Travel Award to attend Emergency Surgery Clerkship at University Clinical Hospital,

Zaragoza, Spain, 1991

World Health Organization (IFMSA) Funding: Full room and board for 1 month.

Page 12 of 31

. Scholarship for Academic Excellence University of Cairo

Funding: Monthly Stipend, 1987-1992 (award renewed annually)

• University of Cairo Admission Scholarship

Funding: Monthly Stipend, 1986-1987

• American University in Cairo Admission Scholarship, Mechanical Engineering Funding: University Tuition Fees, 1985 (Declined in favor of Medical School)

Page 13 of 31

RESEARCH:

Basic Science Research

07/2000 – 7/2002 CIHR (MRC) Fellow Canadian Institutes of Health Research

Ottawa Health Research Institute, Ottawa Hospital University of Ottawa

Division of Neurosciences Successfully competed and obtained funding (~$120,000) from the premier national research

funding agency in Canada, the Canadian Institutes of Health Research (formerly the Medical Research Council of Canada). My grant proposal was ranked 6th nationwide.

My project focused on investigating the molecular mechanisms governing stem cell proliferation and differentiation in the dentate gyrus of rats following traumatic and ischemic cell injury. I was

able to show for the first time that sodium-potassium pump inhibition up-regulates proliferative activity of stem cells in the subgranular zone of the dentate gyrus. I also showed that in the early

stages post-injury, precursor cells undergo an accelerated rate of migration towards areas of cell injury. These findings may have important functional implications in neural network reconstruction following brain damage. Techniques used in this project include

electrophysiological recordings from acute brain slices, immunofluorescence, in situ hybridization, confocal imaging, digital image analysis and stereotactic CNS micro-infusions.

07/1997 - 07/2000 Research Assistant and PhD Student University of Ottawa

Loeb Health Research Institute, Ottawa Hospital Division of Neurosciences

My research focused on elucidating the mechanisms of ischemic neuronal injury. I was successful in developing a novel in-vivo model for acute ischemic stroke which involved the

stereotactic infusion of ouabain (a sodium-potassium ATPase pump blocker) with fluorescent molecular probes into the dentate gyrus of adult rats. This model allowed for the delineation of the cellular and molecular responses of neurons to ischemic injury, and allowed the visualization

of lipid bilayer and DNA conformational changes post-injury. I subsequently utilized this model to study the mechanisms of mannitol-based neuroprotection particularly its effects on sodium

and potassium ion regulation in neurons.

Page 14 of 31

Clinical Research (Selected trials as PI or co-investigator)

Glioblastoma Multiforme

• Avastin and Temozolomide following Radiation and Chemotherapy for Newly Diagnosed

Glioblastoma Multiforme: A Phase II Study

Avastin, a monoclonal antibody angiogenesis inhibitor is added to the standard of care treatment of temozolomide chemotherapy to determine the safety and effectiveness of the combination. Patients may receive treatment until progression or unacceptable toxicities.

• Avastin , Temozolomide, Bevacizumab and RT followed by Temozolomide and Avastin

versus Avastin and Temodar vs. RT/TMZ + placebo followed by TMZ plus placebo for

newly diagnosed GBM: International, muticenter, randomized, double blinded placebo

controlled trial (AVAGLIO)

Study name: AvaGlio (Avstin in Glioblastoma). This is an International phase III trial (the largest trial of its kind for the treatment of Glioblastoma (GBM), the most aggressive brain cancer) examining the efficacy of adding Avastin (a drug that chokes off blood supply to brain cancer) to

standard tx. for newly diagnosed GBM patients. Attended European Investigator meeting in Vienna, Austria (June 15-18, 2009) representing Northshore University HealthSystem, USA as

one of the US study sites that participated in this international trial (one of 143 centers worldwide). In Vienna, I was able to point out a critical problem with the study design that was previously overlooked by the international study team and as a result an amendment was

resubmitted to the FDA for approval

• A Phase II Study of CDX-110 with Radiation and Temozolomide in Patients with Newly

Diagnosed Glioblastoma Multiforme: Phase II/III

CDX110 is a vaccine which recognizes the protein EGFRvIII in GBM. The purpose is to

determine effectiveness and side effects of adding CDX-110 to the standard of care treatment for GBM. Patients will receive Temodar days 1-5 of a 28-day cycle and the CDX-110 vaccine on day 21 of each cycle. Treatment may continue with Temodar for up to one year and the vaccine

continues until progression or unacceptable toxicities.

• Temozolomide Alone and in Combination with Possible Permutations of Thalidomide,

Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy for Glioblastoma

Multiform

The purpose of this study is to compare treatment of temozolomide with the combination and the above mentioned drug to determine the efficacy and safety of these combinations.

Page 15 of 31

. A Phase I Study of Temozolomide and RAD001C in Patients With Malignant

Glioblastoma Multiforme, Sponsor: National Cancer Institute of Canada

Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by

blocking blood flow to the tumor. Giving temozolomide together with everolimus may kill more tumor cells.

This phase I trial is studying the side effects and best dose of everolimus when given together

with temozolomide in treating patients with newly diagnosed, recurrent, or progressive malignant glioblastoma multiforme.

• Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma,

Sponsor: Eli Lilly and Company

This protocol will test the activity of Enzastaurin vs. Lomustine in the treatment of recurrent brain cancer (specifically intracranial glioblastoma multiforme).

• The Temozolomide RESCUE STUDY: A Phase II Trial of Continuous (28/28) Dose-

Intense Temozolomide (CDIT) Chemotherapy After Progression on Conventional 5/28

Day Temozolomide in Patients With Recurrent Malignant Glioma, Sponsor: Schering-

Plough, Schering Canada, Inc.

The purpose of this non-randomized, open-label, multicenter, Phase II, 2-stage design, RESCUE study is to test the hypothesis that continuous 28-day oral dosing (28/28) with dose-intense

temozolomide (50 mg/m2) for up to 12 months may overcome resistance and be effective in the management of adult patients with malignant glioma who have failed following at least 2 cycles (2 months) of conventional 5-day (5/28) cycles of high-dose temozolomide (150-200 mg/m2).

Recurrent Glioblastoma Multiforme

• Ayman Omar, MD, Principal Investigator. NovoTTF100A in combination with

Bevacizumab for the treatment of recurrent glioblastoma. Grant for $5000 from

NovoCure. May 2013.

This project involves developing a novel treatment approach for the treatment of

recurrent GBM patients. The method involves combining the NovoTTF-100A system which delivers alternating electric fields to the brain tumor with bevacizumab, a VEGF inhibitor.

• Phase III, Randomized, Parallel Group, Multicenter Study in Recurrent Glioblastoma

Patients to Compare the Efficacy of Cediranib (Recentin, AZD2171) Monotherapy and

the Combination of Cediranib with Lomustine to the Efficacy of Lomustine Alone

Cediranib is a highly potent and selective VEGF signaling inhibitor that targets all three VEGF

Page 16 of 31

receptors.2 VEGF signaling is a key driver of angiogenesis - the formation of new blood vessels that tumors need to grow and spread.

Low Grade Gliomas • Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low

Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study, Sponsor:

European Organization for Research and Treatment of Cancer and the National Cancer

Institute of Canada.

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the

cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective than temozolomide in treating gliomas.

This randomized phase III trial is studying radiation therapy to see how well it works compared to temozolomide in treating patients with gliomas.

Metastatic Brain Cancer

• Evaluating the Treatment Effects of Surgery plus GLIADEL Wafer in Patients with

Metastatic Brain Cancer

The purpose of this study is to find out the effects of surgery and the placement of Gliadel wafers

on the neurocognitive function of patients with metastatic brain cancer. NeuroOphthalmology Research

• Role of tetracycline in the treatment of chronic progressive external ophthalmoplegia

(CPEO)". Principal Investigator: Lenworth Johnson, Professor of Ophthalmology

(Neuro-Ophthalmology) and Neurology, University of Missouri - Columbia. Co-

Investigator: A.I. Omar, Neurology Chief Resident, University of Missouri - Columbia.

University of Missouri IRB Project #: 1059518. (1/06/ - 7/06)

This is a retrospective analysis of the effect of tetracycline antibiotics on ocular motility in chronic progressive external ophthalmoplegia. CPEO is a hereditary mitochondrial myopathy that results in progressive weakness of the extraocular muscles involved in eye movement.

Patients with CPEO have limited eye movements which can result in double vision, difficulty with reading and gait disturbance. These symptoms are chronic and progressive, as the name

implies, and can be debilitating for patients affected by this condition. To date, there are no available effective treatment options for this disease. Some of our patients have been treated with tetracycline and have had apparent improvement in eye movement. After retrospectively

analyzing the data, we have shown for the first time that tetracycline can play a role in improving ocular motility and in delaying progression of the disease.

Page 17 of 31

TEACHING EXPERIENCE: Southern Illinois University School of Medicine

June 2010 - Present

Author of senior clinical competency exam case, “Intracranial hypotension secondary to a spinal CSF leak”, July 2013. This case is part of the 4th year medical student clinical competency assessment.

Headache lecture to family practice residents 5/8/13

MS lecture to Internal Medicine Residents on 5/20/13

Resident teaching on the inpatient service

Resident clinic supervision. Teaching of Neuroscience course for Neurology Residents

Medical Student teaching: CNS tumors lecture

Medical student teaching on inpatient and outpatient services

Resident supervision during Journal Clubs Examiner: Resident NEX exams (American Board of Psychiatry and Neurology)

Director of Neurological Oncology resident elective rotation

Director of NeuroImmunology and Multiple Sclerosis resident elective rotation

NeuroOncology: The Essentials, 5 1-hr lectures from March 19-23, 2012 to Neurology residents

Lectures on Multiple Sclerosis to Neurology residents February 21, 2012 Lectures on Neurologic complications of HIV to Neurology residents, May 2012

Lectures on evaluation and management of pituitary tumors to Neurology Residents at SIU, May

2012

Page 18 of 31

University of Chicago July 1, 2009 – March 31, 2010

Teaching Medical Residents and Medical students on in- and outpatient services

Northwestern University, Feinberg School of Medicine

August 1, 2008 – June 30, 2009

Resident, medical student and physician assistants teaching /supervision on medical wards as well as classroom lectures, bedside demonstrations and supervision of patient related procedures.

University of Toronto, Faculty of Medicine

July 1, 2006 – June 30, 2008 Supervised residents as Fellow in Neurological Oncology

Supervised a medical student from Germany for 1 month as part of a University of Toronto

international medical student exchange program

University of Missouri - Columbia July 1, 2002 – June 30, 2006

Taught medical students as floor and consulting Neurology Resident.

Taught Introduction to Physical Diagnosis and Advanced Physical Diagnosis (APD) to 1st and 2nd year medical students

CSF Dynamics and Intracranial Pressure course, February 2, 2006, Posted online WebCT, University of Missouri – Columbia

University of Ottawa, Faculty of Medicine January, 1998 – June, 2002

Teaching Assistant: Neurology Block (MED2104; Course Director: Prof. W. Hendelman, 01/1999 - 02/2000)

This position involved teaching the "Neurology block" to 2nd year medical students which included theoretical Neuroanatomy, Neurology, and Neuroradiology case studies as well as cadaver specimens and laboratory demonstrations.

Supervised medical students and lab trainees in Neuroscience research techniques including

immunofluorescence, tissue processing, stereotactic brain infusions, confocal microscopy techniques (Laboratory of Bin Hu, MD, PhD).

Page 19 of 31

CME (selected)

04/29/2009 Annual Meeting - 5PC.005: Neurodevelopmental Disabilities Across the Lifespan 3.50

04/08/2006 Annual Meeting - 8AC.007: Therapeutic Poisoning: Immunosuppressive Therapy for

Non- 3.50 04/07/2006 Annual Meeting - 7SC.001: Future of Neuroscience Conference: Stem Cells and

Neurological diseases 7.50 04/06/2006 Annual Meeting - 6BS.002: Neuro-oncology Update 1.50

04/05/2006 Annual Meeting - 5PC.004: Diagnosis, Management, and Rehabilitation of Traumatic Brain Injury 3.50

04/09/2005 Annual Meeting - 5CS.001 Multiple Sclerosis and Related Disorders: A Case-Based

Approach 3.00 04/09/2005 Annual Meeting - 6CS.003 Unusual Diagnostic and Management Problems in

Neuromuscular Disorders 3.00 04/09/2005 Annual Meeting - 6PC.002 Neurological Complications of Medical Disease 3.50

04/09/2005 Annual Meeting - 7FC.001 Genetics in Neurology 6.50

04/09/2005 Annual Meeting - 8AC.004 Structure Function Correlations in Behavioral Neurology 3.50

6/16/2012 Improving the Frontline Management of Multiple Sclerosis: Case Studies for the

Practicing Clinician – Med-IQ Obtained 30 credits through maintenance of certification program of the Royal College of

Physicians and Surgeons of Canada – 15th International Symposium on Pediatric NeuroOncology – Toronto, Canada – June 24-27, 2012

Update on NovoTTFTM Therapy Efficacy and Safety for Recurrent GBM: Commercial Registry Data" on Wednesday, May 21, 2014, Webinar presented by Eilon Kirson, MD, PhD, Head of

R&D and Chief Science Officer, Novocure, Inc.

Page 20 of 31

PROFESSIONAL AFFILIATIONS:

. American Academy of Neurology, Section of NeuroOncology, member since 2009

· American Academy of Neurology (AAN), member since 2003 (Active) . Society for NeuroOncology (SNO), USA, member since 2008

. College of Physicians and Surgeons of Ontario (CPSO), Canada (member 2006 - 2008)

· Society for Neuroscience (SFN), USA: member since 2000 (Inactive)

· American Physiological Society (major affiliation with CNS section): member since 1999 (Inactive)

· Egyptian Medical Syndicate (Fully Licensed Physician), Egypt: member since 1996

OTHER ACADEMIC ACTIVITIES:

. Consulting Member of Advisory Board, Novocure Ltd., Portsmouth, NH, Development of NovoTTF-100A technology for the management of Glioblastoma, December 7, 2013 –

December 6, 2014

. Member of Advisory Board, EMD Serono. Current management of glioblastoma multiforme in the community practice setting, May 14, 2013.

EDITORIAL BOARD AND JOURNAL REVIEWER

. Associate Editor, Journal of Neurology and Neurosurgery - Open Access, June 2016 - Present

. Reviewer, Journal of Spine, September, 2013 – Present

. Reviewer, Journal of Visualized Experiments, November 2014 – Present

. Reviewer, Journal of Vascular Medicine and Surgery, November 2014 - Present . Reviewer, Journal of Gastrointestinal Diseases, April 2016 - Present

Page 21 of 31

LANGUAGES AND TRAVEL:

Fluent: English and Arabic. Knowledge of: French, Serbian, Romanian and Persian.

Lived and visited the following countries either for education, business, or pleasure: China, Japan, Mongolia, Iran, India, Pakistan, Kuwait, Jordan, Egypt, Morocco, Sweden, Finland, Denmark, Norway, Germany, Austria, Netherlands, Belgium, Luxembourg, France, England,

Bulgaria, Romania, Yugoslavia, Spain, Greece, Italy, Canada, and the United States.

COMPUTER SKILLS:

OS Platforms: Windows 95/98, ME, MS Dos, MacOs, NT. Applications: Wordprocessing Software (MS Word, WordPerfect), Statistical Analysis Software

(Excel, Sigma Plot), Image Acquisition and Analysis (NIH Image, Northern Eclipse, etc.), Image Processing, Computer Graphics and Animation (Adobe Photoshop, Corel Photopaint/Corel Draw

etc.), Presentation (Power Point). Internet: Professional Medline Searches, Netscape, Explorer. Web Page Design: HyperText Markup Language (HTML), Java Script Programming, C++

Programming (Created software for diagnosing fetal distress in high risk pregnancies; copyrighted

CLINICAL PROCEDURAL SKILLS:

Mastered various procedural skills including: Internal Medicine Skils:

Thoracentesis, paracentesis, arthrocentesis, bone marrow biopsies, phlebotomy, peripheral IV

line access, femoral central lines, EKG hookup and interpretation, advanced airway management including intubation as well as various ACLS skills (advanced airway management, rhythm interpretation and ACLS management, operating AEDs and manual defibrillators, synchronized

cardioversion, transcutaneous pacing, management of Acute Coronary Syndromes and stroke per AHA guidelines, etc.). ATLS skills: chest tube insertions and evaluation and management of

various traumas including head traumas.

Page 22 of 31

Basic Surgical Skills:

Including suturing and wound closure, abscess drainage etc., also assisted in some neurosurgical procedures during a 2 month Neurosurgery internship rotation including VP shunt and

ventriculostomy placement as well as some craniotomies for evacuation of epidural hematomas etc.

Neurology Skills:

Lumbar punctures (over 1000 procedures to date), Baclofen intrathecal infusions as part of trial for Baclofen pump surgery, Tensilon tests, EEG and sleep studies interpretation, performing and

interpreting nerve conduction studies as well as EMG of extremities and paraspinal muscles. Excellent skills in neuroimaging interpretation (CTs, MRI/MRA head and neck etc.). Use of

immunomodulatory agents including interferons, Gilenya and Tysabri infusions (registered physician through the FDA mandated TOUCH program), occipital nerve blocks, evaluation and management of acute strokes, intracranial hemorrhage, critical care neurology, etc..

Completed an intensive 1 month training in Critical Care/Intensive Care Neurology at Barnes

Jewish Hospital, Washington University in St. Louis, October 2005 (Barnes Jewish is ranked as one of the top 10 hospitals in the United States). Patients managed included gunshot wounds to the head, ruptured cerebral aneurysms, Traumatic brain injury, Brain abscesses, intracranial

bleeds, patients requiring emergency neurosurgical interventions, pre and post-procedure care for patients undergoing neurendovascular procedures such as cerebral angioplasty/ stenting and

coiling of intracranial aneurysms, etc.

NeuroOncology Skills:

Extensive knowledge of chemotherapeutic agents, their methods of administration, potential toxicities and their management

Management of neurologic complications related to systemic cancer

Diagnosis and management of Primary Brain Tumors (over 120 different subtypes)

Special expertise in the management of Primary CNS Lymphomas

Knowledge of radiation therapy utilization for the treatment of brain and spinal cord cancers including Whole Brain Radiation Therapy (WBRT), Stereotactic Radiosurgery as well as Intensity Modulated Radiation Therapy (IMRT) for the treatment of brain cancer adjacent to

critical brain structures.

Extensive knowledge of chemotherapy, radiotherapy and immunotherapy for the treatment of primary central nervous system lymphomas including the use of monoclonal antibodies that

Page 23 of 31

target molecules specific to cancer cells.

Extensive knowledge in the treatment of leptomeningeal metastatases (spread of systemic cancer to the brain coverings as well as the cerebrospinal fluid) including the use of Ommaya reservoirs

intraventricular chemotherapy infusion. Recognized as an expert in the treatment of leptomeningeal cancer (co-authored a book chapter in the leading international Cancer Neurology reference textbook, Cancer Neurology in Clinical Practice.

Developed a “Brain Metastases Clinic” at the NorthShore University HealthSytem, the first

Brain Metastases Clinic in the State of Illinois. Certified as a “clinical center of excellence” provider of a novel brain cancer treatment technique

involving the delivery of electromagnetic waves using electrode arrays placed on patients skull using NovoTTF-100a device. This is an FDA approved treatment. I’m currently the only

provider of this technology in central and southern Illinois and one of approximately 40 centers nationwide. http://www.novottftherapy.com/patients-centers.php

Neuroimmunology Skills: Directed SIU Multiple Sclerosis clinic (2011-2013)

Extensive knowledge in treatment of demyelinating diseases such as multiple sclerosis

Knowledge in use of Tysabri infusions, use of interferons, Gilenya, chemotherapeutic agents for the treatment of MS, etc.

University Boards and Committees

• Member and Reviewer, Springfield Committee on Research Involving Human Subjects (SCRIHS IRB): Role is to review clinical research proposals in the Springfield area and ensure they meet local, institutional and FDA and international guidelines (June 2010 – July 2013)

• Member, Senior Clinical Competency Committee (CCX Curriculum Committee), Southern

Illinois University School of Medicine. Role is to develop clinical competency exams for senior graduating medical students.

• Developed Neurological Oncology Tumor Board (first in Southern Illinois University): Currently moderating a bimonthly board meeting comprised of Neurosurgeons, Radiation

Oncologists, Medical Oncologists, Neuroradiologists, Neuropathologists and myself as Neurological Oncologist and Tumor Board moderator. This tumor board is approved for AMA CME credits (June 2010 – Present).

Page 24 of 31

• Member, Simmons Cancer Institute: Operating and directing a Neurological Oncology service

at SCI (July 2010 – July 2013).

• Member, Data Safety Monitoring Board for Evaluation of 5-alpha levulinic acid as an intraoperative fluorescent marker during glioma surgery, PI: Jeffrey Cozzens, MD

PUBLICATIONS:

Page 25 of 31

Peer-Reviewed Journal Articles:

1. A. I. Omar, Tumor Treating Field Therapy in Combination with Bevacizumab for the

Treatment of Recurrent Glioblastoma. J. Vis. Exp. (92), e51638, doi:10.3791/51638 (2014). http://www.jove.com/video/51638/tumor-treating-field-therapy-combination-with-bevacizumab-for

2. A. I. Omar, Holmes-Adie Syndrome in the Setting of Induced Hypothermia is Associated

with Delayed Recovery from General Anesthesia. Open Access J Neurol Neurosurg. 2016; 1(2): 555558.

3. A.I. Omar. Molecular pathways in malignant gliomas: Targets for rational anticancer drug design (In Preparation)

4. A.I. Omar, J. Cozzens, B. Moore. Molecular characterization and response to treatment

of a primary CNS lymphoma (In Submission)

5. A.I. Omar. Complicated migraine with complex regional pain syndrome after

craniospinal irradiation for medulloblastoma: A possible SMART variant. (In Submission)

6. Ayman I. Omar, Pankaj Jalan, Vijay Pandav, Simon Bekker. Extensive venous sinus thrombosis in a patient with sinonasal undifferentiated carcinoma with a dural-based

metastasis. (In Submission)

7. P. Jalan, P Bhargava, Asa and A.I. Omar. Successful treatment of dermato-neuro

syndrome associated with scleromyxedema with intravenous immunoglobulin: A proposed mechanism of action (– In review)

8. P. Jalan, V. Pandav, L. Dhakkal, A. Omar. Status migrainosus as a potential stressor

leading to Takutsubo cardiomyopathy. Cephalalgia, 2012 Nov;32(15):1140-3. Epub 2012

Sep 18.

9. A.I. Omar. Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma. Journal of Medical Case Reports 2012, 6:238. (Received Highly Accessed designation by BioMed Central – A designation given to highly accessed

articles relative to their age and journal in which they were published) Article also chosen by MDLinx (www.MDLinx.com) for a news feed informing

clinicians of important developments in the surgical field

10. A.I. Omar and W.P. Mason. Temozolomide: The evidence for its therapeutic efficacy in

malignant astrocytomas, Core Evidence 2009:4 93–111

11. A.I. Omar, L.N. Johnson. Tetracycline delays ocular motility decline in chronic progressive external ophthalmoplegia. (Neurology, 2007; 68: 1159)

Page 26 of 31

12. Mooney DM, Zhang L, Basile C, Senatorov VV, Ngsee J, Omar AI, Hu B.. Distinct forms

of cholinergic modulation in parallel thalamic sensory pathways. Proc. Natl. Acad. Sci. U S A. 2004 Jan 6;101(1):320-4. Epub 2003 Dec 22. (Chosen by Faculty of 1000 as one of

the most important scientific articles in Neuroscience - Sherman S: 2004. F1000.com/1016818#eval201453)

13. A.I. Omar and B. Hu. Detection of early tissue injury in vivo using fluorescent cell death markers in rat dentate gyrus. Neurosci Lett. 2003 Sep 18;348(3):143-6.

14. A.I. Omar, V.V. Senatorov, and B. Hu. Sodium-potassium adenosine triphosphatase

inhibition enhances membrane accumulation of DiI in rat hippocampus in vivo.

Neuroscience 102 (2), 353-359. (2001)

15. A.I. Omar, V.V. Senatorov, and B. Hu. Ethidium bromide staining reveals rapid cell dispersion in the rat dentate gyrus following ouabain-induced injury. Neuroscience 95 (1), 73-80. (2000)

PHD DISSERTATION

1. A.I. Omar. Tissue injury and remodeling in rat hippocampal dentate gyrus following Na+,

K+, ATPase Inhibition. PhD Dissertation, University of Ottawa, Faculty of Medicine, Dissertation Abstracts International and the National Library of Canada, (Advisor: Bin

Hu, MD, PhD) (©2002). Dissertation Nominated by Reviewers for University Award.

MASTERS THESIS

1. A. I. Omar, Endovascular NeuroOncology: A new frontier for the management of brain and spinal cord malignancies, University of Oxford, MSc. In Endovascular Neurosurgery, 2016

2. A. I. Omar, Endovascular Neurosurgery Operative Techniques: Logbook of Cases,

University of Oxford, Interventional Neuroradiology, 2016

Book Chapters and Reviews:

1. A.I. Omar and W.P. Mason. Anaplastic astrocytomas – Neurooncology (M.J. Aminoff, F.

Boller and D.F. Swaab, eds.), Elsevier Press, Handbook of Clinical Neurology, 2012;105:

451-66.

2. A.I. Omar and W.P. Mason. Leptomeningeal Metastases in Cancer Neurology in Clinical

Page 27 of 31

Practice (David Schiff, MD, Patrick Y. Wen, MD and Santosh Kesari,MD, PhD, eds.), Humana Press Inc., Totowa, NJ., (© 2007)

3. A.I. Omar and W.P. Mason. Glial Tumors: Low-grade and anaplastic oligodendrogliomas, International Neurology (M. Rosenfeld, MD and J. Dalmau, MD, eds.)

4. A.I. Omar and W.P. Mason. The Molecular Basis For The Genesis Of Malignant Gliomas: Targets For Novel Anti-Cancer Therapeutics. Oncology Rounds (2006)

Abstracts:

1. Ayman I Omar. Targeting the vascular endothelial growthfactor pathway for the treatment

of surgically unresectable spinal cord hemangioblastomas. Submitted to the American Academy of Neurology meeting in San Diego, March 16-23, 2013.

2. Ayman I. Omar, Pankaj Jalan, Vijay Pandav, Simon Bekker. Extensive venous sinus thrombosis in a patient with sinonasal undifferentiated carcinoma with a dural-based

metastasis. Society for NeurOncology 2012 annual meeting, Nov. 15-18, Washington, DC (Pesented poster abstract to be published in NeuroOncology, the official SNO journal)

3. A.I. Omar. Complicated migraine with complex regional pain syndrome after

craniospinal irradiation for medulloblastoma: A possible SMART variant. (Neuro Oncol (2012) 14 (suppl 1): i125-i139: Abstracts from the 15th International Symposium on Pediatric Neuro-Oncology, June 24-27 2012 Toronto, Ontario, Canada)

4. A.I. Omar. Bevacizumab for the treatment of surgically unresectable cervical cord

hemangioblastoma. Neuro Oncol (2011) 13 (suppl 3):iii41- iii68, Abstract presented at the 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the American Association of Neurological Surgeons/CNS Section on Tumors,

Orange County, California, November 17-20, 2011

5. M. K. Nicholas, R. V. Lucas, J. Arzbaecher, N. Paleologos, H. Krouwer, M. Malkin, A.I. Omar, N. A. Vick. Bevacizumab in combination with temozolomide in the adjuvant treatment of newly diagnosed glioblastoma multiforme: Preliminary results of a phase II

study. J Clin Oncol 27:15s, 2009 (suppl; abstr 2016)

6. A.I. Omar and L.N. Johnson. Tetracycline delays the decline in ocular motility in chronic progressive external ophthalmoplegia. (16th International Neuro-ophthalmology Society (INOS) Congress 2006, Neuro-opthalmology, Volume 30, Number 6, 2006)

7. A.I. Omar, C. Basile, J. Ngsee, D. Mooney, and B. Hu. Differential expression of m1 and m2 muscarinic receptors in rat leminiscal and non-lemniscal medial geniculate body. Soc.

Page 28 of 31

Neurosci. Abstr. Vol. 28, Orlando, FL. (November 2002)

8. A.I. Omar and B. Hu. Monitoring DNA condensation in vivo using the DNA fluorescent probe Hoechst 33342 following ouabain-induced injury. Soc. Neurosci. Abstr. Vol. 27,

San Diego, CA. (November 2001)

9. A.I. Omar and B. Hu. Intrahippocampal ouabain infusion upregulates proliferatvie

activity of the subventricular zone progenitor cell population. Soc. Neurosci. Abstr. Vol. 26, Part I, p. 286. Presented at the Society For Neuroscience 30th annual meeting, New

Orleans, LA. (November 4-9, 2000)

10. A.I. Omar and B. Hu. Evidence for a lesion-induced accelerated migration of newly born

precursor cells in adult rat dentate gyrus. EB 2000 Abstr. Add. Presented at the "Experimental Biology 2000" Conference, San Diego, CA. (April 2000)

11. A.I. Omar, V.V. Senatorov, and B. Hu. Enhanced membrane uptake of a lipophilic

fluorescent probe following intrahippocampal ouabain administraion: A possible in vivo

marker for membrane damage. Soc. Neurosci. Abstr. Vol. 25, Part I, p. 995. Presented at the Society for Neuroscience 29th annual meeting, Miami Beach, FL. (October 23-28,

1999)

12. A.I. Omar, V.V. Senatorov, M. Tiberi, and B. Hu. Rapid induction of granule cell

dispersion in the dentate gyrus of the adult rat hippocampal formation by ouabain. Soc. Neurosci. Abstr. Vol. 24, Part I, p. 718. Presented at the Society for Neuroscience 28th

annual meeting, Los Angeles, CA. (November 7-12, 1998)

Presentations:

1. A.I. Omar. Cerebral arterial anatomy, University of Oxford Tutorials, October 2014

2. A.I. Omar. Cerebral venous anatomy, University of Oxford Tutorials, October 2014

3. A.I. Omar. Control of cerebral blood flow, University of Oxford Tutorials, November 2014

4. A.I. Omar. Dangerous extracranial to intracranial anasomoses, University of Oxford

Tutorials, November 2014

5. A.I. Omar, E. Karroum and B. Moore. Sellar Masses. Clinical Pathology Conference

(Grand Rounds). 2013

Page 29 of 31

6. Melikyan and A.I. Omar. Journal Club. SIU School of Medicine 2/18/2013. Antoniol

C, Jilek S, Schluep M, et al. Impairment of JCV-specific T-cell response by

corticotherapy: effect on PML-IRIS management? Neurology. 2012 Dec 4;79(23):2258-

64

7. A.I. Omar and Suzanna Johnston. Management of Recurrent Glioblastomas with

Electromagnetic Tumor Treating Fields: A Novel Treatment with NovoTTF-100A Device.

Neurology and Neurosurgery Grand Rounds. Southern Illinois University School of

Medicine. January 29. 2012

8. A.I. Omar. Examination of the Comatose Patient. Lecture presented to second year

medical students. SIU School of Medicine, January 24, 2013

9. A.I. Omar, S. Dandapat and B. Moore. Meningioma mimics. Clinical Pathology

Conference (Grand Rounds). December 4, 2012

10. A.I. Omar and L. Dhakal. Inflammatory Demyelinating Brain Lesions Heralding Primary CNS Lymphoma. Grand Rounds (Journal Club). May 15. 2012

11. A.I. Omar and L. Dhakal. Clinical Pathology Conference (Grand Rounds). March 6,

2012, The Road from PhD to Dementia: Alzheimers with posterior cortical atrophy admixed with diffuse Lewy body disease pathology. Southern Illinois University School of Medicine.

12. A.I. Omar. Clinical Pathology Conference (Grand Rounds). January 3, 2012, 20 year old

with intractable seizures: Ganglioglioma intermixed with an arteriovenous malformation – Angioglioma? Southern Illinois University School of Medicine.

13. A.I. Omar. Advances in the management of brain metastases. Neurology and Neurosurgery Grand Rounds, November, 2011, Southern Illinois University School of

Medicine.

14. A.I. Omar. Bevacizumab for the treatment of surgically unresectable cervical cord

hemangioblastoma: A novel approach. Neurology and Neurosurgery Grand Rounds, June 2011, Southern Illinois University School of Medicine.

15. A.I. Omar. Current Management Strategies for Malignant Astrocytomas. Neurology and

Neurosurgery Grand Rounds, April 25, 2011, Southern Illinois University School of

Medicine.

16. V Sabodash and A.I. Omar. Grand Rounds (Journal Club). Transcranial Magnetic Stimulation. March 2011, Southern Illinois University School of Medicine.

Page 30 of 31

17. A.I. Omar. Clinical Pathology Conference (Grand Rounds). April, 2011, Unusual presentation for an intraventricular mass lesion. Southern Illinois University School of

Medicine.

18. A.I. Omar. Rapid Onset of Obstructive Hydrocephalus and Seizures in an Otherwise Healthy Female Patient. 10/6/2008. Clinical Neurosciences conference, NorthShore University HealthSystem and Northwestern University Feinberg School of Medicine

19. A.I. Omar. Brain metastases: The current state of knowledge. 12/11/08. Medicine Grand

Rounds, NorthShore University HealthSystem and Northwestern University Feinberg School of Medicine

20. A.I. Omar. Neuro-HIV. 3/21/09, Clinical Neurosciences conference, NorthShore University HealthSystem and Northwestern University Feinberg School of Medicine

21. A.I. Omar. Molecular approaches for the treatment of malignant astrocytomas: From the

bench to the bedside. Neurology/Neurosurgery Grand Rounds. University of Missouri -

Columbia (April 26, 2006)

22. A.I. Omar. New-onset seizures in a young female: A diagnostic challenge. Neurology/Neurosurgery Grand Rounds. University of Missouri - Columbia (November 23, 2005)

23. A.I. Omar. Guidelines for the management of the severely head-injured patient.

Neurology/Neurosurgery Grand Rounds. University of Missouri - Columbia (October 6, 2004)

24. A.I. Omar. Critical care strategies in traumatic brain injury. Invited speaker at the Division of Pulmonary and Critical Care Medicine. University of Missouri - Columbia.

(October 19, 2004)

25. A.I. Omar. Injury induced remodeling in the Central Nervous System. Neurology/

Neurosurgery Grand Rounds, University of Missouri, Columbia, Missouri. (April, 2004)

26. A.I. Omar and B. Hu. Local and distant tissue remodeling in rat hippocampus following ouabain-induced injury. Presented at the University of Ottawa, Cellular and Molecular Medicine Seminars. (April 18, 2001)

27. A.I. Omar and B. Hu. Early tissue reactive changes following sodium-potassium

adenosine triphosphatase pump inhibition in the adult rat dentate gyrus. Presented at the University of Ottawa, Cellular and Molecular Medicine Seminars. (November 2000)

28. A.I. Omar. Journal Club Presentation: Presented at the "Neurotalks" meeting at the Loeb Health Research Institute, Ottawa, Canada. (October 5, 2000) Prenatal stress produces

learning deficits associated with an inhibition of neurogenesis in the hippocampus. V. Lemaire et al. Proc. Natl. Acad. Sci. USA, Vol. 97, Issue 20, 11032-11037. (2000)

Page 31 of 31

29. A.I. Omar and B. Hu. Dynamics of lesion-induced proliferation and cellular

reorganization in the adult rat brain. Presented at the University of Ottawa, Cellular and Molecular Medicine Seminars. (December 1999)

30. A.I. Omar and B. Hu. In vivo cellular and molecular responses to Na+, K+, ATPase Pump

blockade in the rat dentate gyrus. Presented at the University of Ottawa, Faculty of

Medicine seminar series. (April 1999)

31. A.I. Omar, V.V. Senatorov, and B. Hu. Ouabain induces rapid cell dispersion and network remodeling in the adult rat hippocampal formation. Presented at the University of Ottawa, Faculty of Medicine seminar series. (April 1998)